RSR13 plus cranial radiation therapy in patients with brain metastases: Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database

Journal of Clinical Oncology

Volumn 21, Issue 12, 2003, Pages 2364-2371

  Shaw, Edward ^a   Scott, Charles ^a   Suh, John ^a   Kadish, Sidney ^a   Stea, Baldassarre ^a   Hackman, John ^a   Pearlman, Andrew ^a   Murray, Kevin ^a   Gaspar, Laurie ^a   Mehta, Minesh ^a   Curran, Walter ^a   Gerber, Michael ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAPROXIRAL; ANILINE DERIVATIVE; PROPIONIC ACID DERIVATIVE; RADIOSENSITIZING AGENT;

ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DRUG SAFETY; FATIGUE; FOLLOW UP; HEADACHE; HUMAN; HYPOXIA; INTRACRANIAL HYPERTENSION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; BRAIN TUMOR; COMPARATIVE STUDY; FEMALE; MALE; METASTASIS; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE FRACTIONATION; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANILINE COMPOUNDS; BRAIN NEOPLASMS; DOSE FRACTIONATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROPIONIC ACIDS; RADIATION-SENSITIZING AGENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038149435     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.116     Document Type: Article

References (36)

1. Arbit E, Wronski M, Burt M, et al: The treatment of patients with recurrent brain metastases: A retrospective analysis of 109 patients with nonsmall cell lung cancer. Cancer 76:765-773, 1995
2. Posner JB: Management of brain metastases. Rev Neurol 148:477-487, 1992
3. Davey P: Brain metastases. Curr Probl Cancer 23:59-98, 1999
4. Gaspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997
5. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999
6. Kurtz JM, Gelber R, Brady LW, et al: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:891-895, 1981
7. Nieder C, Berberich W, Schnabel K: Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 39:25-30, 1997
8. Hall ET: The oxygen effect and reoxygenation in radiobiology for the radiologist (ed 3). Philadelphia, PA, Lippincott, 1988
9. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
10. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41:31-39, 1996
11. Stadler P, Becker A, Feldmann HJ, et al: Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 44:749-754, 1999
12. Fyles AW, Milosevic M, Wong R, et al: Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48:149-156, 1998
13. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29:427-431, 1994
14. De Santis M, Balducci M, Basilico L, et al: Radiotherapy, local control and survival in brain tumors. Rays 23:543-548, 1998
15. 2 tension measurements. Cancer Res 51:6098-6102, 1991
16. Gatenby RA, Kessler HB, Rosenblum JS, et al: Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14:831-838, 1988
17. 2 tension measurements. Cancer Res 51:3316-3322, 1991
18. Abraham DJ, Peascoe RA, Randad RS, et al: X-ray diffraction study of di and tetra-ligated T-state hemoglobin from high salt crystals. J Mol Biol 227:480-492, 1992
19. Teicher BA, Ara G, Emi Y, et al: RSR13: Effects on tumor oxygenation and response to therapy. Drug Dev Res 38:1-11, 1996
20. 2 and decreases arteriolar diameter and flow in the rat cremaster muscle. Microvasc Res 52:58-68, 1996
21. 2 delivery in dog muscle in situ. J Appl Physiol 84:995-1002, 1998
22. Rockwell S, Kelley M: RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: Preliminary studies with EMT6 cells and tumors and normal tissues in mice. Radiat Oncol Investig 6:199-208, 1998
23. Gaspar LE, Scott C, Murray K, et al: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001-1006, 2000
24. Harwood AR, Simson WJ: Radiation therapy of cerebral metastases: A randomized prospective clinical trial. Int J Radiat Oncol Biol Phys 2:1091-1094, 1977
25. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9, 1980
26. Borgelt B, Gelber R, Larson M, et al: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 7:1633-1638, 1981
27. Chatani M, Teshima T, Hata K, et al: Prognostic factors in patients with brain metastases from lung carcinoma. Strahlenther Onkol 162:157-161, 1986
28. Haie-Meder C, Pellae-Cosset B, Laplanche A, et al: Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 26:111-116, 1993
29. Chatani M, Matayoshi Y, Masaki N, et al: Radiation therapy for brain metastases from lung carcinoma: Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 170:155-161, 1994
30. Murray KJ, Scott C, Greenberg HM, et al: A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: A report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 39:571-574, 1997
31. DeAngelis LM, Currie VE, Kim JH, et al: The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 7:241-247, 1989
32. Komarnicky LT, Phillips TL, Martz K, et al: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20:53-58, 1991
33. Phillips TL, Scott CB, Leibel SA, et al: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33:339-348, 1995
34. Ushio Y, Arita N, Hayakawa T, et al: Chemotherapy of brain metastases from lung carcinoma: A controlled randomized study. Neurosurgery 28:201-205, 1991
35. Mehta MP, Rodrigus P, Terhaard C, et al: Results from the phase III trial of motefaxin gadolinium (MGd) in brain metastases. Proc Am Soc Clin Oncol 72a, 2002 (abstr)
36. Kleinberg L, Grossman SA, Piantadosi S, et al: Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme. J Clin Oncol 17:2593-2603, 1999